Great Point Partners LLC Takes Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Great Point Partners LLC acquired a new stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 248,168 shares of the company’s stock, valued at approximately $1,263,000. Eliem Therapeutics accounts for approximately 0.4% of Great Point Partners LLC’s holdings, making the stock its 28th largest position. Great Point Partners LLC owned approximately 0.83% of Eliem Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ELYM. Advantage Alpha Capital Partners LP bought a new position in shares of Eliem Therapeutics during the 3rd quarter valued at about $245,000. The Manufacturers Life Insurance Company bought a new stake in shares of Eliem Therapeutics in the 3rd quarter worth approximately $252,000. Valence8 US LP purchased a new stake in shares of Eliem Therapeutics in the 3rd quarter valued at $61,000. Charles Schwab Investment Management Inc. raised its position in Eliem Therapeutics by 309.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 70,093 shares of the company’s stock worth $357,000 after purchasing an additional 52,965 shares during the period. Finally, Segall Bryant & Hamill LLC purchased a new stake in Eliem Therapeutics during the third quarter valued at about $297,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Trading Down 1.3 %

ELYM opened at $3.04 on Wednesday. Eliem Therapeutics, Inc. has a 12 month low of $2.35 and a 12 month high of $11.55. The business’s 50-day moving average price is $4.79 and its 200-day moving average price is $6.52. The company has a market cap of $90.45 million, a P/E ratio of -5.74 and a beta of -0.39.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.